Thyroid and Cardiovascular Risk

Wendy P. J. den Elzen, Simon P. Mooijaart, Bart E. P. B. Ballieux, Anne R. Cappola, Jacobijn Gussekloo

Research output: Chapter in Book/Report/Conference proceedingChapterAcademicpeer-review

Abstract

Here we present data on the clinical effects of abnormalities in thyroid hormone levels on cardiovascular risk, focusing on the risks associated with subclinical thyroid dysfunction. Some observational studies and randomized clinical trials have suggested that subclinical hypothyroidism causes reversible alterations in surrogate markers of cardiovascular disease such as lipid levels and carotid intima media thickness. RCTs and meta-analyses to date have not shown effects of levothyroxine treatment for patients with subclinical hypothyroidism on clinical and cardiovascular outcomes, but were underpowered to detect effects on cardiac events and mortality. Observational data strongly support the treatment of subclinical hyperthyroidism to prevent atrial fibrillation and heart failure, but the degree to which the cardiovascular risk is reversible is unknown since prospective, randomized controlled trials of treatment of subclinical hyperthyroidism are not available.
Original languageEnglish
Title of host publicationThyroid and Heart: A Comprehensive Translational Essay, Second Edition
PublisherSpringer International Publishing
Pages205-227
ISBN (Electronic)9783030368715
ISBN (Print)9783030368708
DOIs
Publication statusPublished - 1 Jan 2020
Externally publishedYes

Publication series

NameThyroid and Heart: A Comprehensive Translational Essay, Second Edition

Cite this